[{"id":"7e6819a5-0a0e-4ce4-b697-04b501a41ea6","acronym":"GT-30","url":"https://clinicaltrials.gov/study/NCT04251117","created_at":"2024-04-19T18:51:54.179Z","updated_at":"2025-02-25T17:24:31.308Z","phase":"Phase 1/2","brief_title":"GNOS-PV02 Personalized Neoantigen Vaccine, INO-9012 and Pembrolizumab in Subjects with Advanced HCC","source_id_and_acronym":"NCT04251117 - GT-30","lead_sponsor":"Geneos Therapeutics","biomarkers":" IFNG","pipe":"","alterations":" ","tags":["IFNG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • rocakinogene sifuplasmid (INO-9012) • GNOS-PV02"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 03/01/2020","start_date":" 03/01/2020","primary_txt":" Primary completion: 11/29/2024","primary_completion_date":" 11/29/2024","study_txt":" Completion: 11/29/2028","study_completion_date":" 11/29/2028","last_update_posted":"2025-01-31"}]